Literature DB >> 27106681

Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders.

Cherrie Galletly1, David Castle2, Frances Dark3, Verity Humberstone4, Assen Jablensky5, Eóin Killackey6, Jayashri Kulkarni7, Patrick McGorry8, Olav Nielssen9, Nga Tran10.   

Abstract

OBJECTIVES: This guideline provides recommendations for the clinical management of schizophrenia and related disorders for health professionals working in Australia and New Zealand. It aims to encourage all clinicians to adopt best practice principles. The recommendations represent the consensus of a group of Australian and New Zealand experts in the management of schizophrenia and related disorders. This guideline includes the management of ultra-high risk syndromes, first-episode psychoses and prolonged psychoses, including psychoses associated with substance use. It takes a holistic approach, addressing all aspects of the care of people with schizophrenia and related disorders, not only correct diagnosis and symptom relief but also optimal recovery of social function.
METHODS: The writing group planned the scope and individual members drafted sections according to their area of interest and expertise, with reference to existing systematic reviews and informal literature reviews undertaken for this guideline. In addition, experts in specific areas contributed to the relevant sections. All members of the writing group reviewed the entire document. The writing group also considered relevant international clinical practice guidelines. Evidence-based recommendations were formulated when the writing group judged that there was sufficient evidence on a topic. Where evidence was weak or lacking, consensus-based recommendations were formulated. Consensus-based recommendations are based on the consensus of a group of experts in the field and are informed by their agreement as a group, according to their collective clinical and research knowledge and experience. Key considerations were selected and reviewed by the writing group. To encourage wide community participation, the Royal Australian and New Zealand College of Psychiatrists invited review by its committees and members, an expert advisory committee and key stakeholders including professional bodies and special interest groups.
RESULTS: The clinical practice guideline for the management of schizophrenia and related disorders reflects an increasing emphasis on early intervention, physical health, psychosocial treatments, cultural considerations and improving vocational outcomes. The guideline uses a clinical staging model as a framework for recommendations regarding assessment, treatment and ongoing care. This guideline also refers its readers to selected published guidelines or statements directly relevant to Australian and New Zealand practice.
CONCLUSIONS: This clinical practice guideline for the management of schizophrenia and related disorders aims to improve care for people with these disorders living in Australia and New Zealand. It advocates a respectful, collaborative approach; optimal evidence-based treatment; and consideration of the specific needs of those in adverse circumstances or facing additional challenges. © The Royal Australian and New Zealand College of Psychiatrists 2016.

Entities:  

Keywords:  Schizophrenia; first-episode psychosis; management; schizoaffective; treatment

Mesh:

Year:  2016        PMID: 27106681     DOI: 10.1177/0004867416641195

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  117 in total

1.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

2.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

3.  Paliperidone Long-Acting Injections in Huntington's Disease for Motor and Behavioural Disturbances.

Authors:  Nameer van Oosterom; Theo Theodoros
Journal:  Clin Drug Investig       Date:  2019-04       Impact factor: 2.859

4.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 5.  Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management.

Authors:  Kathlyn J Ronaldson
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

6.  Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.

Authors:  Adriana Foster; Peter Buckley; John Lauriello; Stephen Looney; Nina Schooler
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

7.  Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Authors:  Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

8.  A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia.

Authors:  Mark Taylor; Hannah Chu-Han Huang
Journal:  Ther Adv Psychopharmacol       Date:  2017-07-31

Review 9.  Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Authors:  Chen-Chung Liu; Hiroyoshi Takeuchi
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

10.  Cost-Effectiveness of Routine Screening for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States.

Authors:  Eric L Ross; Jessica E Becker; Jenny J Linnoila; Djøra I Soeteman
Journal:  J Clin Psychiatry       Date:  2020-11-17       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.